Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07570654 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Study acronym: Redefine
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 4 → 8 locations
  2. Study sites: 2 to 4 Eligibility criteria expanded, about 2 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 2 words
  3. Study sites: 1 to 2v4
  4. Recruitment openedv3
  5. Eligibility criteria shortened, about 4 wordsv2 See this version in full on ClinicalTrials.gov ↗
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
COMPASS Pathways
4 trials monitored
See all monitored trials
PTSD
821 trials monitored
See 49 trials at risk
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
Trial Details
NCT Number NCT07570654
Lead Sponsor COMPASS Pathways
Conditions PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov